PFIZER INC.
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About the Safety and Effects of Rimegepant to Prevent Migraine in Chinese Subjects.
- First Posted Date
- 2023-04-12
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 776
- Registration Number
- NCT05810038
- Locations
- π¨π³
The Second People's hospital of Hefei, Hefei, Anhui, China
π¨π³The fourth people's hospital of chongqing, Chongqing, Chongqing, China
π¨π³Beijing Friendship Hospital, Capital Medical University, Beijing, Beijing, China
A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults
- First Posted Date
- 2023-04-11
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 86
- Registration Number
- NCT05807490
- Locations
- πΊπΈ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
π§πͺPfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, RΓ©gion DE, Belgium
To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults
- Conditions
- Clostridoides Difficile Associated Disease
- Interventions
- Biological: C. difficile vaccine formulation 1.Biological: C. difficile vaccine formulation 2.Biological: C. difficile vaccine formulation 3.Biological: C. difficile vaccine (previously studied formulation).Other: Saline Placebo.
- First Posted Date
- 2023-04-10
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 689
- Registration Number
- NCT05805826
- Locations
- πΊπΈ
HOPE Research Institute, Phoenix, Arizona, United States
πΊπΈHope Research Institute, Phoenix, Arizona, United States
πΊπΈThe Pain Center of Arizona, Phoenix, Arizona, United States
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized
- First Posted Date
- 2023-04-05
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 240
- Registration Number
- NCT05799495
- Locations
- πΊπΈ
Remington-Davis, Inc, Columbus, Ohio, United States
πΊπΈProactive Clinical Research LLC, Edinburg, Texas, United States
πΊπΈFranco Felizarta, Md, Bakersfield, California, United States
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
- Conditions
- Crohn DiseaseArthritis, RheumatoidColitis, UlcerativePsoriasis
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2207
- Registration Number
- NCT05796245
- Locations
- π―π΅
Pfizer, Tokyo, Japan
A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV
- Conditions
- HIVPneumoniaInfections, Pneumococcal
- Interventions
- Biological: Vaccine Administration
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05794191
- Locations
- πΊπΈ
Pfizer, New York, New York, United States
Treatment Patterns Among Patients With Venous Thromboembolism in the United States
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 13945
- Registration Number
- NCT05795062
- Locations
- πΊπΈ
Pfizer, New York, New York, United States
A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 16
- Registration Number
- NCT05788328
- Locations
- πΊπΈ
Qps-Mra, Llc, South Miami, Florida, United States
A Study to Examine Respiratory Combination Vaccines Against Respiratory Syncytial Virus (RSV) and Flu in Older Adults
- Conditions
- Healthy
- Interventions
- Biological: RSVpreF+qIRVBiological: RSVpreF + qIRV 1.0 mL formulationDrug: PlaceboBiological: RSVpreF + qIRV 0.5 mL formulation
- First Posted Date
- 2023-03-28
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 508
- Registration Number
- NCT05788237
- Locations
- π¦π·
Hospital Militar Central Cirujano Mayor Dr. Cosme Argerich, Buenos Aires, Argentina
A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.
- Conditions
- Breast Cancer
- First Posted Date
- 2023-03-15
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT05770713
- Locations
- π¨π¦
Pfizer Canada, Kirkland, Quebec, Canada